Medical Breakthroughs Reported by Ivanhoe.com. Click here to go to the homepage.
Be the First to Know. Click here to subscribe FREE!
Search Reports: Use quotation marks around your multi-word search terms in the box below to perform search of Ivanhoe.com.
Advances in health and medicine.Use " marks around search terms
 
What's New
News Flash
Discussion
healthchannelnews
  Alternative Health
Arthritis
Asthma & Allergies
Autism
Breast Cancer
Cancer
Cardiovascular Health
Children's Health
Dental Health
Diabetes
Fertility & Pregnancy
Men's Health
Mental Health
Multiple Sclerosis
Neurological Disorders
Nutrition & Wellness
Orthopedics
Pet Health
Robotics
Seniors' Health
Sports Medicine
Vision
Women's Health
Advances in health and medicine.
Click here to sign up for Medical Alerts!
Click below to access other news from Ivanhoe Broadcast News.
  Click here to get Ivanhoe's Medical Headline RSS feed Click here to listen to Ivanhoe's Medical Podcasts
Useful Links
Play It Again, Please
E-Mail a Friend
Order Books Online
Inside Science
Smart Woman
Advances in health and medicine.
Smart Woman Home
Click here to read the story
Click here to read the story
Click here to read the story
Smart Woman Home
Advances in health and medicine.
Click below to learn about Ivanhoe.
  Awards
About Us
Contact Us
Employment
Feedback
Ivanhoe FAQ
Our TV Partners
Travel Calendar
Advances in health and medicine.
Ivanhoe celebrates 20 years of medical news reporting reaching nearly 80 million TV households each week. Click here to learn more...
Advances in health and medicine.
Marjorie Bekaert Thomas
Publisher/President
Advances in health and medicine.
Advertisement
Cancer Channel
Reported July 11, 2012

New Drug Stunts Tumor Growth

By: Erika Dunayer, Ivanhoe Health Consultant

(Ivanhoe Newswire) -- Cancer is a leading cause of death globally. Now, researchers are breaking ground on new ways to cut off the ability for cancer cells to grow.

RNA Polymerase I (Pol I) activity is essential for cancer cell survival. Scientists are discovering that its inhibition selectively activates p53 (tumor suppressor protein) to kill tumors. Cylene Pharmaceuticals, founded by Daniel Von Hoff the worlds leading clinical oncologist, has found that the Pol I inhibitor, CX-5461, selectively destroys cancer by activating p53 in malignant cells but not in normal cells.

"What we found is that the drug (CX-5461) can selectively kill the tumor cells. It activates p53, which is the guardian of the genome, activating p53 is something everyone strives for, and as it turns out, that’s how this drug works," Dr. William G. Rice, PhD, President and CEO of Cylene Pharmaceuticals, told Ivanhoe.

"We collaborated with the team at the Peter MacCallum Centre in Melbourne, Australia and together we validated that Pol 1 is a true target for cancer. Even a modest reduction in Pol 1 selectively kills cancer cells but not normal cells and that was really a major finding to show that you can reduce Pol 1 in cancer cells and it kills them but it does not kill normal cells," Dr. Rice said.

Studies were done in vivo (within the living) models of blood cancers and demonstrated that the drug removed malignant cells from the bloodstream, while allowing normal healthy blood cells to grow, thus differentiating CX-5461 from genotoxic treatments. Targeting cancer's dependence upon Pol I to trigger cancer-specific activation of p53 signifies an entirely new approach to cancer therapy.

"It's a completely new concept to treating cancer," Rice told Ivanhoe. "Identifying the target (Pol 1), understanding that it is a validated cancer target, developing the drug, showing that it selectively kills tumor cells and not normal cells, and now we have even been able to determine genetic marker cells which means that we will be able to select the most beneficial patients. It is unusual to have all of those elements meet at one time."

This drug will be clinically tried in human patients in just a couple of months. The Peter MacCallum Cancer Center in Melbourne Australia received a grant from the Australian Government to support this first-in-human trial.

"It's a major step forward to be able to move this into humans so quickly and we are just thrilled to be able to offer a new class of drugs to cancer patients. We really have the potential here to save lives and that is very exciting," Rice said.

Source: Ivanhoe Interview with Dr. William G. Rice, PhD, President and CEO of Cylene Pharmaceuticals on July11, 2012

Related Articles in Latest Medical News:

[ Back to Cancer Channel Home ]

MEDICAL ALERT!
Stay up to date on Cancer. We can notify you every time there is a medical breakthrough. Click here to sign up.
EDITOR'S CHOICE
Advertisement

Follow Us On:

Click here to go to Ivanhoe's Twitter page Click here to go to Ivanhoe's Facebook page Click here to go to Ivanhoe's YouTube page

Home | What's New | News Flash | Search/Latest Medical News | E-Mail Medical Alerts!
Ivanhoe FAQ | Privacy Policy | Our TV Partners | Awards | Useful Links | Play It Again, Please
RSS Feeds | Advertising/Sponsorships | Content Syndication | Reprints

Advances in health and medicine.
webdoctor@ivanhoe.com
Copyright © 2014 Ivanhoe Broadcast News, Inc.
2745 West Fairbanks Avenue
Winter Park, Florida 32789
(407) 740-0789

P.O. Box 865
Orlando, Florida 32802

Premium Content in Latest Medical News Denotes Premium Content in Latest Medical News